Under graduated in Medicine from Botucatu Medical School of São Paulo State University - UNESP (1977), specialist in Tropical Medicine by the School of Medicine of University of São Paulo (1979), Master (MSc 1984) and Doctor (PhD 1986) in Internal Medicine by UNESP. Associate (1993) and Full Professor (1999) of Infectology at Botucatu Medical School - UNESP. He is a Researcher at The Center for the Study of Venoms and Venomous Animals at UNESP (CEVAP), Editor-in-chief of The Journal of Venomous Animals and Toxins including Tropical Diseases (BMC-Springer-Nature) (http://jvat.biomedcentral.com/ ) – Impact Factor Web of Science, JCR® 2017 = 1.782, CiteScore Scopus 2017 = 1.95, First quartile (Q1) at Animal Science and Zoology, and Full Professor of Infectious and Parasitic Diseases at the Botucatu Medical School – UNESP. He has experience in Toxinology, Tropical Medicine, Clinical Research and Scientific Publishing working mainly in the following Disciplines: Infectious and Parasitic Diseases, Toxinology (envenomations by venomous animals), Clinical Research (clinical trials), Scientific writing and publishing. Founder and Director of The Center for the Study of Venoms and Venomous Animals at UNESP (CEVAP), (Director in 1993-1997, 2006-2014 and 2018-2021), Pro-Dean of University Extension (2001-2004) and President of the Brazilian Association of Scientific Editors - ABEC (2008- 2012). From 2005 he became coordinator of the Research Group on Toxinology certified by UNESP and CNPq, as well as President of the Lucentis Foundation for Culture, Education, Research and Extension. From 2014 approved and became deputy coordinator of the National Institute of Science and Technology of Wildlife Science Center (WSC), CNPq 465429/2014-9. Currently coordinate two phase I/II clinical trials named respectively: Use of the fibrin biopolymer in the treatment of chronic venous ulcers and, Use of the new apilic antivenom to treat massive Africanized honeybee (Apis mellifera) attack. The fibrin biopolymer and apilic antivenom have been in development for more than 20 years in partnership with Instituto Vital Brazil of Rio de Janeiro (RJ). In 2018, the Ministry of Health approved the construction of the Biological Drug Samples Factory for Clinical Trials at CEVAP-UNESP. The agreement 873706/2018 was established between Caixa Econômica Federal and UNESP, and the construction begins this year yet.